PLC recognizes Elgan Pharma’s recent announcement on their recent positive Phase III study results

02 March 2022 – PLC recognizes Elgan Pharma’s recent announcement on their recent positive Phase III study results. The study met primary and secondary endpoints of orally delivered ELGN-GI in preterm infants for the treatment of intestinal malabsorption. PLC supports Elgan Pharma with their current clinical development and regulatory filings in the US.

Elgan Pharma Announces Positive Results from its Phase III Study of ELGN-GI in Preterm Infants for Treatment of Intestinal Malabsorption

https://www.biospace.com/article/releases/elgan-pharma-announces-positive-results-from-its-phase-iii-study-of-elgn-gi-in-preterm-infants-for-treatment-of-intestinal-malabsorption/

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Related Posts

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

Congratulations to Neurelis on their accepted presentations at the upcoming Annual Meeting of the American Academy of Neurolgy

PLC recognizes Neurelis’ recent announcement concerning first dosing of their first-in-human study to treat patients with cerebral cavernous malformation (CCM) with NRL-1049, a Rho kinase (ROCK) inhibitor